[go: up one dir, main page]

MX2023010540A - Uso de mevidaleno y otros moduladores alostéricos positivos d1 en el tratamiento de alucinaciones y psicosis relacionadas con la demencia. - Google Patents

Uso de mevidaleno y otros moduladores alostéricos positivos d1 en el tratamiento de alucinaciones y psicosis relacionadas con la demencia.

Info

Publication number
MX2023010540A
MX2023010540A MX2023010540A MX2023010540A MX2023010540A MX 2023010540 A MX2023010540 A MX 2023010540A MX 2023010540 A MX2023010540 A MX 2023010540A MX 2023010540 A MX2023010540 A MX 2023010540A MX 2023010540 A MX2023010540 A MX 2023010540A
Authority
MX
Mexico
Prior art keywords
mevidalen
hallucinations
treatment
dementia
positive allosteric
Prior art date
Application number
MX2023010540A
Other languages
English (en)
Inventor
Kevin Michael Biglan
Kjell Anders Ivan Svensson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2023010540A publication Critical patent/MX2023010540A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se relaciona con métodos de tratamiento y regímenes de dosificación usando mevidaleno, también descrito como 2- (2,6-diclorofenil)-1-[(1S,3R)-3-(hidroximetil)-5-(3-hidrox i-3- metilbutil)-1-metil-3,4-dihidroisoquinolin-2(1H)-il]etanona, y/o composiciones farmacéuticas de este, para el tratamiento de alucinaciones y/o psicosis, incluida la psicosis relacionada con la demencia.
MX2023010540A 2021-03-08 2022-03-08 Uso de mevidaleno y otros moduladores alostéricos positivos d1 en el tratamiento de alucinaciones y psicosis relacionadas con la demencia. MX2023010540A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163157966P 2021-03-08 2021-03-08
PCT/US2022/019308 WO2022192231A1 (en) 2021-03-08 2022-03-08 Use of mevidalen and other d1 positive allosteric modulators in the treatment of hallucinations and dementia-related psychosis

Publications (1)

Publication Number Publication Date
MX2023010540A true MX2023010540A (es) 2023-11-24

Family

ID=80930548

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023010540A MX2023010540A (es) 2021-03-08 2022-03-08 Uso de mevidaleno y otros moduladores alostéricos positivos d1 en el tratamiento de alucinaciones y psicosis relacionadas con la demencia.

Country Status (10)

Country Link
US (1) US20240299375A1 (es)
EP (1) EP4304581A1 (es)
JP (1) JP2024509448A (es)
KR (1) KR20230154967A (es)
CN (1) CN117377470A (es)
AU (1) AU2022234744B2 (es)
BR (1) BR112023018175A2 (es)
CA (1) CA3211261A1 (es)
MX (1) MX2023010540A (es)
WO (1) WO2022192231A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA60976B1 (fr) 2020-10-07 2024-05-31 Lilly Co Eli Dérivés de la phényl-3,4-dihydroisoquinoléine-2(1h)-yl-éthan-1-one comme modulateurs allostériques positifs du récepteur d1 de la dopamine
CN116283804B (zh) * 2022-11-09 2025-05-13 武汉科技大学 具有湿度稳定性和溶解度优势的氯氮平共晶及其制备方法
CN118359538A (zh) * 2023-04-18 2024-07-19 上海赛默罗生物科技有限公司 异喹啉类化合物、其制备方法、药物组合物和用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3316B1 (ar) 2013-05-30 2019-03-13 Lilly Co Eli مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل
PL3204359T3 (pl) 2014-10-08 2021-03-22 UCB Biopharma SRL Pochodne tetrahydroizochinoliny
AR106332A1 (es) 2015-10-23 2018-01-03 Lilly Co Eli Forma cristalina de 2-(2,6-diclorofenil)-1-[(1s,3r)-3-(hidroximetil)-5-(3-hidroxi-3-metilbutil)-1-metil-3,4-dihidroisoquinolin-2(1h)-il]etanona
AU2019256351B2 (en) 2018-04-20 2024-02-29 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
MD3897578T2 (ro) * 2018-12-18 2025-04-30 Lilly Co Eli Regimuri de dozare pentru utilizarea LY3154207 în tratamentul tulburărilor dopaminergice ale SNC

Also Published As

Publication number Publication date
BR112023018175A2 (pt) 2023-10-31
AU2022234744B2 (en) 2025-06-26
JP2024509448A (ja) 2024-03-01
EP4304581A1 (en) 2024-01-17
CN117377470A (zh) 2024-01-09
KR20230154967A (ko) 2023-11-09
CA3211261A1 (en) 2022-09-15
US20240299375A1 (en) 2024-09-12
AU2022234744A1 (en) 2023-09-14
WO2022192231A1 (en) 2022-09-15

Similar Documents

Publication Publication Date Title
MX2023010540A (es) Uso de mevidaleno y otros moduladores alostéricos positivos d1 en el tratamiento de alucinaciones y psicosis relacionadas con la demencia.
PH12022551379A1 (en) Substituted tetrahydrofurans as modulators of sodium channels
EA202190630A1 (ru) Способы комбинированной терапии
GEP20247638B (en) Pharmaceutical combination of prmt5 inhibitors
PH12019500056A1 (en) 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
EA201170670A1 (ru) Аминотетрагидропираны в качестве ингибиторов дипептидилпептидазы-iv для лечения или предупреждения диабета
PH12022550271A1 (en) Solid forms of an hpk1 inhibitor
MY168791A (en) Carbamate compounds and of making and using same
PH12020500666A1 (en) Pladienolide compounds and their use
MA50406B1 (fr) Inhibiteurs pyrazole de magl
MA35716B1 (fr) Formulations pharmaceutiques
JOP20200252A1 (ar) مركبات مساعدة لعامل تمايز النمو 15 وطرق استخدامها
MA53427B1 (fr) Inhibiteurs de l'arginase et leurs méthodes d'utilisation
NZ792518A (en) Formulations for administration of eflornithine
PH12018500859A1 (en) Crystalline form of 2-(2,6-dichlorophenyl)-1-[(1s,3r)-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl-3,4-dihydroisoquinolin-2(1h)-yl]ethanone for the treatment of parkinson`s disease
JOP20200015A1 (ar) توليفة علاجية من مثبط كيناز تيروسين egfr من الجيل الثالث ومثبط كيناز يعتمد على سيكلين
MA43313B1 (fr) Aza-hétérocyclique à 6 éléments contenant des composés modulateurs de récepteurs opioïdes delta, et leurs procédés de fabrication et d'utilisation
EA201492097A1 (ru) 5-амино[1,4]тиазины в качестве ингибиторов бета-секретазы 1
PH12019501642A1 (en) Novel compounds and their use in the treatment of schistosomiasis
SA521431128B1 (ar) -1-[(1s، 3r)-3-عمليات ومركبات وسيطة لتحضير 2-(2، 6-داي كلورو فينيل) (هيدروكسي ميثيل)-5-(3-هيدروكسي-3-ميثيل بيوتيل)-1-ميثيل-3، 4-داي هيدروأيزو كوينولين -يل]إيثانون-2(1h)
MA39447A1 (fr) (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
MA39448B1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
MX2023010542A (es) Uso de mevidaleno y otros moduladores alostéricos positivos d1 para ralentizar la progresión de la enfermedad de parkinson.
MY209771A (en) Compounds for use in the treatment of fascioliasis
EA201792558A1 (ru) Противогрибковый 4-(4-(4-(((3r,5r)-5-((1h-1,2,4-триазол-1-ил)метил)-5-(2,4-дифторфенил)тетрагидрофуран-3-ил)метокси)-3-метилфенил)пиперазин-1-ил)-n-(2-гидроксициклогексил)бензамид или его фармацевтически приемлемая соль